Tumor Regression and Cure Depends on Sustained Th1 Responses

While immunomodulatory monoclonal antibodies (mAbs) have therapeutic efficacy against many tumors, few patients are cured. Attempting to improve their therapeutic efficacy we have applied the TC1 mouse lung carcinoma model and injected established subcutaneous tumors intratumorally with 3 weekly dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Min, Hellstrom, Ingegerd, Yip, Yuen Y., Sjögren, Hans Olov, Hellstrom, Karl Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Basic Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133214/
https://www.ncbi.nlm.nih.gov/pubmed/29912725
http://dx.doi.org/10.1097/CJI.0000000000000231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133214/
https://www.ncbi.nlm.nih.gov/pubmed/29912725
http://dx.doi.org/10.1097/CJI.0000000000000231

Ejemplares similares